SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Significant Segment Expenses (Details) - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | ||||
|---|---|---|---|---|---|---|
Sep. 30, 2026 |
Sep. 30, 2025 |
Sep. 30, 2026 |
Sep. 30, 2025 |
|||
| Segment Reporting Information [Line Items] | ||||||
| Total Research and development expense | $ 2,118 | $ 3,278 | $ 6,816 | $ 10,096 | ||
| Total Selling, general and administrative expense | 1,339 | 2,012 | 6,449 | 5,733 | ||
| Total operating expenses | 3,457 | 5,290 | 13,265 | 15,829 | ||
| Reportable Segment | ||||||
| Segment Reporting Information [Line Items] | ||||||
| Employee expenses | 2,046 | 2,949 | 8,293 | 8,821 | ||
| Consulting and professional fees | 319 | 546 | 1,192 | 1,220 | ||
| Clinical study expenses | 19 | 92 | 278 | 297 | ||
| Product development | 4 | 677 | 207 | 2,032 | ||
| Other | [1] | 315 | 313 | 903 | 951 | |
| Total Research and development expense | 657 | 1,628 | 2,580 | 4,500 | ||
| Selling, general and administrative expenses | 513 | 477 | 1,570 | 1,804 | ||
| Commercialization readiness expenses | 241 | 236 | 822 | 704 | ||
| Total Selling, general and administrative expense | 754 | 713 | 2,392 | 2,508 | ||
| Total operating expenses | $ 3,457 | $ 5,290 | $ 13,265 | $ 15,829 | ||
| ||||||
| X | ||||||||||
- Definition Segment Reporting, Clinical Study Expenses No definition available.
|
| X | ||||||||||
- Definition Segment Reporting, Commercialization Readiness Expenses No definition available.
|
| X | ||||||||||
- Definition Segment Reporting, Research and Development Expense, Product Development No definition available.
|
| X | ||||||||||
- Definition Amount of expense for employee benefit and equity-based compensation. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of general and administrative expense classified as other. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of other research and development expense. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|